Syngene International Ltd.
NSE: SYNGENESyngene International Ltd.: A 30-second snapshot
Syngene trades at Rs 414.25, down 39.0% over the past 12 months and 42.98% below its 52-week high, below both its 50-DMA (Rs 434.82) and 200-DMA (Rs 509.01). Trailing PE of 52.70 (forward 32.86) sits against an ROE of 6.62%, a 5-year earnings CAGR of -19.4%, and debt-to-equity of 9.47x, with a quality score of 19 that ranks 5th of 6 tracked Pharma peers. Recent news flow centers on a CEO transition from Peter Bains to Siddharth Mittal, alongside Q1 FY27 results reported July 29, 2026.
P/E
52.7
Forward P/E
32.9
ROE
+6.6%
Debt / Equity
9.47
Profit Margin
+8.5%
Div. Yield
+0.3%
5Y ROE > 15%
0/5
5Y FCF > 0
4/5
Quality
40/100
News
8 headlines · 3 positive · 2 negative
Syngene International Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 - marketscreener.com
marketscreener.com
Syngene International MD & CEO Peter Bains resigns - economictimes.com
economictimes.com
Syngene CEO Peter Bains resigns as part of leadership succession plan - Business Standard
Business Standard
Siddharth Mittal steps in as Managing Director & CEO of Syngene International - BioSpectrum India
BioSpectrum India
Siddharth Mittal Takes Charge As Syngene International MD & CEO - BW Healthcare World
BW Healthcare World
Recent context
- ·Q1 FY27 results (quarter ended June 30, 2026) were reported on July 29, 2026, per marketscreener.com coverage.
- ·MD & CEO Peter Bains resigned as part of a leadership succession plan (Economic Times, Business Standard, July 3, 2026); Siddharth Mittal was named MD & CEO effective July 2-3, 2026 (BioSpectrum India, BW Healthcare World).
- ·News sentiment across the 8 tracked articles was split 3 positive / 3 neutral / 2 negative, with an overall label of neutral.
Strengths
- +Free cash flow was positive in 4 of the last 5 measured years, even as reported earnings growth over the same window was -19.4%.
- +Debt-to-equity trend is classified as falling, even though the absolute ratio remains elevated at 9.47x.
- +RSI of 43.78 sits in neutral territory, with price holding above nearby support levels at Rs 406.40 and Rs 378.93.
- +Leadership succession was completed with a named replacement: Siddharth Mittal was announced as MD & CEO immediately following Peter Bains' resignation on July 2-3, 2026, per Business Standard and BioSpectrum India.
Weaknesses
- −Debt-to-equity of 9.47x is materially elevated for a pharma-CRO business, alongside an ROE of 6.62% that has not exceeded 15% in any of the measured years.
- −5-year earnings CAGR of -19.4% and 5-year revenue growth of just 1.8% mark the weakest growth profile among the 6 tracked Pharma peers, while the stock still trades at a trailing PE of 52.70 and forward PE of 32.86.
- −Price of Rs 414.25 has been below both the 50-DMA (Rs 434.82) and 200-DMA (Rs 509.01), down 39.0% over 12 months and 42.98% off its 52-week high.
- −Quality score of 19 ranks 5th of 6 tracked Pharma peers (only Dr. Reddy's, at 4, is lower), with an 8.47% profit margin among the weakest in the peer set.
Open questions
- ?Does the falling debt trend reflect deleveraging fast enough to bring the 9.47x debt-to-equity ratio toward levels seen at peers such as Cipla or Dr. Reddy's, and over what timeframe?
- ?What operational or contract-pipeline factors might explain the gap between a 52.70 trailing PE and a 5-year earnings CAGR of -19.4%?
- ?How might the CEO transition from Peter Bains to Siddharth Mittal affect strategic priorities such as capacity expansion or the CRO client-contract mix?
- ?With price 42.98% below the 52-week high and holding near support at Rs 406-379, what would a sustained move back above the 200-DMA (Rs 509.01) require in terms of earnings or margin trajectory?
Peer comparison: Pharma
Ranks 5 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| SYNGENE | Syngene International Ltd.You're viewing | 52.7 | +6.6% | 19 |
| Industry avg | across 5 peers | 49.4 | +14.8% | 34 |
| SUNPHARMA | Sun Pharmaceutical Industries Ltd. | 41.6 | +14.7% | 56 |
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd. | 66.0 | +21.5% | 44 |
| MAXHEALTH | Max Healthcare Institute Ltd. | 75.1 | +14.3% | 37 |
| CIPLA | Cipla Ltd. | 35.3 | — | 28 |
| DRREDDY | Dr. Reddy's Laboratories Ltd. | 28.7 | +8.8% | 4 |
Technical state
Current price
₹414.25
SMA 50
₹434.82
SMA 200
₹509.01
RSI (14)
43.8 (neutral)
From 52w high
-43.0%
1Y return
-39.0%
3M return
-13.0%
50-DMA
Below
200-DMA
Below
Algorithmic support levels
Algorithmic resistance levels
Risk flags
- highDebt-to-equity of 9.47x is materially elevated for a pharma-CRO business, paired with an ROE of 6.62% that has not exceeded 15% in any of the measured years (0 of tracked years above that threshold) and a consistency score of 28; the debt trend is classified as falling but the absolute level warrants monitoring.
- medium5-year earnings CAGR of -19.4% and 5-year revenue growth of just 1.8% mark the weakest growth profile among tracked Pharma peers, yet the stock trades at a trailing PE of 52.70 (forward 32.86).
- mediumPrice of Rs 414.25 sits below both the 50-DMA (Rs 434.82) and 200-DMA (Rs 509.01), down 39.0% over 12 months and 42.98% off its 52-week high.
- lowNews sample is limited to 8 tracked articles (3 positive, 3 neutral, 2 negative); sentiment read carries low statistical confidence at this sample size.
Cross-section contradictions
- Trailing PE of 52.70 and forward PE of 32.86 imply an anticipated earnings recovery, yet 5-year earnings CAGR is -19.4% and ROE is 6.62%, with no confirmed operational catalyst bridging that gap in the data reviewed.
- Mean analyst rating of 2.125 across 8 analysts (1-5 scale, lower = more constructive) sits toward the constructive end, while the stock is down 39.0% over 12 months and ranks 5th of 6 tracked Pharma peers on quality score (19).
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 11 Aug 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 30 Jul 2026 · rotates through NIFTY 500 every ~5 days